Recombumin® Prime - rAlbumin Human
Recombinant albumin developed as an excipient for use in drug delivery and formulation. Recombumin Prime is the world's first and only supply of commercial, animal-free, recombinant human albumin, approved for use in the manufacture of human therapeutics.Used in the manufacture of the FDA and EMEA approved MMR™ II childhood vaccine from Merck and Co., Recombumin Prime USP-NF* is also being evaluated as an excipient, or ingred…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Recombinant albumin developed as an excipient for use in drug delivery and formulation.
Recombumin Prime is the world's first and only supply of commercial, animal-free, recombinant human albumin, approved for use in the manufacture of human therapeutics.
Used in the manufacture of the FDA and EMEA approved MMR™ II childhood vaccine from Merck and Co., Recombumin Prime USP-NF* is also being evaluated as an excipient, or ingredient, in several other products undergoing clinical development in the US and EU.
Benefits:
- Stabilize your product in liquid formulation at room temperature
- Improve visual appearance of lyophilized product and decrease dissolving time
- Manufactured to Q7 cGMP in FDA, Health Canada and MHRA inspected facilities
- Extend product bioavailability
- Half-life extension of peptides.
Applications:
- Protein and peptide drug formulation
- Vaccine formulation
- Drug manufacturing ingredient
- Drug targeting and delivery
Improved Stabilization and Reduction of Particulate Formation in Protein Drug Formulations Using Recombinant Human Albumin (rAlbumin Human USP-NF)
This poster demonstrates that a recombinant HSA (rAlbumin) derived from yeast is a safe excipient candidate with a well-documented stabilizing effect including aggregation prevention in liquid and lyophilized protein formulations and also prevention of drug depletion and degradation caused by surface adsorption/effects.
